Abstract

BackgroundEnsuring rapid access to high quality sexual health services is a key public health objective, both in the United Kingdom and internationally. Internet-based testing services for sexually transmitted infections (STIs) are considered to be a promising way to achieve this goal. This study will evaluate a nascent online STI testing and results service in South East London, delivered alongside standard face-to-face STI testing services.ObjectiveThe aim of this study is to establish whether an online testing and results services can (1) increase diagnoses of STIs and (2) increase uptake of STI testing, when delivered alongside standard face-to-face STI testing services.MethodsThis is a single-blind randomized controlled trial. We will recruit 3000 participants who meet the following eligibility criteria: 16-30 years of age, resident in the London boroughs of Lambeth and Southwark, having at least one sexual partner in the last 12 months, having access to the Internet and willing to take an STI test. People unable to provide informed consent and unable to read and understand English (the websites will be in English) will be excluded. Baseline data will be collected at enrolment. This includes participant contact details, demographic data (date of birth, gender, ethnicity, and sexual orientation), and sexual health behaviors (last STI test, service used at last STI test and number of sexual partners in the last 12 months). Once enrolled, participants will be randomly allocated either (1) to an online STI testing and results service (Sexual Health 24) offering postal self-administered STI kits for chlamydia, gonorrhoea, syphilis, and HIV; results via text message (short message service, SMS), except positive results for HIV, which will be delivered by phone; and direct referrals to local clinics for treatment or (2) to a conventional sexual health information website with signposting to local clinic-based sexual health services. Participants will be free to use any other interventions or services during the trial period. At 6 weeks from randomization we will collect self-reported follow-up data on service use, STI tests and results, treatment prescribed, and acceptability of STI testing services. We will also collect objective data from participating STI testing services on uptake of STI testing, STI diagnoses and treatment. We hypothesise that uptake of STI testing and STI diagnoses will be higher in the intervention arm. Our hypothesis is based on the assumption that the intervention is less time-consuming, more convenient, more private, and incur less stigma and embarrassment than face-to-face STI testing pathways. The primary outcome measure is diagnosis of any STI at 6 weeks from randomization and our co-primary outcome is completion of any STI test at 6 weeks from randomization. We define completion of a test, as samples returned, processed, and results delivered to the intervention and/or clinic settings. We will use risk ratios to calculate the effect of the intervention on our primary outcomes with 95% confidence intervals. All analyses will be based on the intention-to-treat (ITT) principle.ResultsThis study is funded by Guy’s and St Thomas’ Charity and it has received ethical approval from NRES Committee London-Camberwell St Giles (Ref 14/LO/1477). Research and Development approval has been obtained from Kings College Hospital NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust. Results are expected in June 2016.ConclusionsThis study will provide evidence on the effectiveness of an online STI testing and results service in South East London. Our findings may also be generalizable to similar populations in the United Kingdom.Trial RegistrationInternational Standard Randomized Controlled Trial Number (ISRCTN): 13354298; http://www.isrctn.com/ISRCTN13354298 (Archived by WebCite at http://www.webcitation.org/6d9xT2bPj)

Highlights

  • At any point in 2008 it was estimated that 100.4 million adults were infected with C. trachomatis, 36.4 million with N. gonorrhoeae, 36.4 million with syphilis and 187.0 million with T. vaginalis

  • At any point in time 2008 it was estimated that 3.0 million adults were infected with C. trachomatis, 1.0 million with N. gonorrhoeae, 1.6 million with syphilis1 and 13.2 million with T. vaginalis

  • This paper presents global and regional prevalence and incidence estimates for four of these infections in 2008

Read more

Summary

Introduction

This report was prepared by Jane Rowley, Igor Toskin and Francis Ndowa. WHO thanks: The WHO STI Regional Advisors: David Mercer, Ulrich Laukamm-Josten and Lali Khotenashvili (WHO Regional Office for Europe), Gabriele Riedner and Hamida Khattabi (WHO Regional Office for the Eastern Mediterranean), Teodora Wi (WHO Regional Office for the Western Pacific), Iyanthi Abeyewickreme (WHO Regional Office for SouthEast Asia), Massimo Ghidinelli, Monica Alonso Gonzalez, Sonja Caffe, Suzanne Serruya and Raul Gonzalez (WHO Regional Office for the Americas) for providing additional data and for reviewing the estimates. This report presents global and regional estimates for 2008 of the incidence and prevalence of four curable STIs – Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis – in adults between 15 and 49 years of age. These estimates were generated using the same approach as used to generate the 2005 global estimates (see World Health Organization, 2011, for a detailed description of these methods). At any point in 2008 it was estimated that 100.4 million adults were infected with C. trachomatis, 36.4 million with N. gonorrhoeae, 36.4 million with syphilis and 187.0 million with T. vaginalis. Global incidence and prevalence of selected curable sexually transmitted infections – 2008 1

Methods
Findings
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call